Show Summary Details
Page of

IVIG versus Plasma Exchange for Myasthenia Gravis 

IVIG versus Plasma Exchange for Myasthenia Gravis
Chapter:
IVIG versus Plasma Exchange for Myasthenia Gravis
Author(s):

Kimberly R. Robeson

DOI:
10.1093/med/9780199377527.003.0023
Page of

PRINTED FROM OXFORD MEDICINE ONLINE (www.oxfordmedicine.com). © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 October 2019

This chapter provides a summary of a landmark study in neuromuscular disease. Which treatment is more effective for patients with worsening myasthenia gravis—intravenous immunoglobulin or plasma exchange? Starting with that question, it describes the basics of the study, including funding, study location, who was studied, how many patients, study design, study intervention, follow-up, endpoints, results, and criticism and limitations. Researchers found that immunomodulation for myasthenia gravis can be accomplished with either of the treatments. Therefore, availability of treatment options and patient’s comorbidities should all be considered when choosing a therapy for worsening myasthenia gravis. The chapter briefly reviews other relevant studies and information, and concludes with a relevant clinical case.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.